Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?

Cha E, Small EJ.

Cancer Med. 2013 Apr;2(2):243-52. doi: 10.1002/cam4.64. Epub 2013 Feb 24. Review.

2.

Prospects for the use of ipilimumab in treating advanced prostate cancer.

Wei XX, Fong L, Small EJ.

Expert Opin Biol Ther. 2016;16(3):421-32. doi: 10.1517/14712598.2016.1136284. Epub 2016 Jan 25. Review.

PMID:
26698365
3.

Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.

Saad F, Miller K.

Urology. 2015 May;85(5):976-86. doi: 10.1016/j.urology.2014.12.029. Epub 2015 Feb 20. Review.

PMID:
25709051
4.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
5.

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms.

Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K.

Urol Oncol. 2015 May;33(5):245-60. doi: 10.1016/j.urolonc.2014.10.009. Epub 2015 Jan 7. Review.

6.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Pennock GK, Chow LQ.

Oncologist. 2015 Jul;20(7):812-22. doi: 10.1634/theoncologist.2014-0422. Epub 2015 Jun 11. Review.

7.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
8.

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.

Lancet Oncol. 2012 May;13(5):501-8. doi: 10.1016/S1470-2045(12)70006-2. Epub 2012 Feb 10.

PMID:
22326924
9.

Immunotherapy in prostate cancer: challenges and opportunities.

Noguchi M, Koga N, Moriya F, Itoh K.

Immunotherapy. 2016;8(1):69-77. doi: 10.2217/imt.15.101. Epub 2015 Dec 7. Review.

PMID:
26642100
10.

Role of immunotherapy in castration-resistant prostate cancer (CRPC).

Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J.

BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110. Epub 2013 Apr 12. Review.

11.

Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.

Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L.

Cancer Immunol Res. 2015 Sep;3(9):1008-16. doi: 10.1158/2326-6066.CIR-14-0227. Epub 2015 May 12.

12.

Beyond sipuleucel-T: immune approaches to treating prostate cancer.

Cheng ML, Fong L.

Curr Treat Options Oncol. 2014 Mar;15(1):115-26. doi: 10.1007/s11864-013-0267-z. Review.

13.

Ipilimumab in prostate cancer.

Singh N, Madan RA, Gulley JL.

Expert Opin Biol Ther. 2013 Feb;13(2):303-13. doi: 10.1517/14712598.2012.754421. Epub 2012 Dec 25. Review.

PMID:
23265575
14.

[Ipilimumab].

Tokudome T.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1140-4. Japanese.

PMID:
24047771
15.

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Spigel DR, Socinski MA.

J Thorac Oncol. 2013 May;8(5):587-98. doi: 10.1097/JTO.0b013e318286cf88. Review.

16.

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM.

Ann Oncol. 2013 Jul;24(7):1813-21. doi: 10.1093/annonc/mdt107. Epub 2013 Mar 27.

17.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

18.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F.

Ann Oncol. 2013 May;24(5):1170-9. doi: 10.1093/annonc/mds647. Epub 2013 Feb 7. Review.

19.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
20.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899

Supplemental Content

Support Center